(MedPage Today) — ORLANDO — Patients with hemophilia B continued to experience low annualized bleeding rates and stable endogenous factor IX expression 5 years after a single infusion of etranacogene dezaparvovec (Hemgenix), the final analysis…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118932
Author :
Publish date : 2025-12-10 17:18:00
Copyright for syndicated content belongs to the linked Source.
